Abstract
1. Disease-Modifying Antirheumatic Drug (DMARD) Designations in RA a. A drug must change the course of the disease for at least 1 year b. Change evidenced by one of the following i. Sustained improvement in physical function ii. Decreased inflammatory synovitis iii. Slowing or prevention of structural joint damage c. Drugs conventionally classified as DMARDs i. Hydroxychloroquine (HCQ) ii. Auranofin iii. Not shown to retard radiologic damage d. Biologic agents i. Considered as DMARDs ii. Favorable impact on structural damage
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag London Limited
About this chapter
Cite this chapter
Colburn, N.T. (2011). Disease-Modifying Antirheumatic Drugs. In: Review of Rheumatology. Springer, London. https://doi.org/10.1007/978-1-84882-093-7_20
Download citation
DOI: https://doi.org/10.1007/978-1-84882-093-7_20
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-84882-092-0
Online ISBN: 978-1-84882-093-7
eBook Packages: MedicineMedicine (R0)